Cancer Research Technology
And commercialises exciting new discoveries in cancer research.
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 98.8m | 113m | 138m | 128m | 110m | 111m | 91.6m |
| % growth | 4 % | 14 % | 22 % | (7 %) | (14 %) | 1 % | (17 %) |
| EBITDA | 40.9m | 55.0m | 43.8m | 38.6m | 38.8m | 20.3m | 21.4m |
| % EBITDA margin | 41 % | 49 % | 32 % | 30 % | 35 % | 18 % | 23 % |
| Profit | 45.7m | 42.3m | 62.3m | 40.9m | 44.2m | 46.3m | 17.1m |
| % profit margin | 46 % | 38 % | 45 % | 32 % | 40 % | 42 % | 19 % |
| R&D budget | - | 2.9m | - | - | - | - | - |
| R&D % of revenue | - | 3 % | - | - | - | - | - |
Related Content
Recent News about Cancer Research Technology
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
